Which molecular alteration is most frequently associated with adenocarcinoma of the lung in non-smoking patients?

Explanation

## Molecular Alterations in Lung Adenocarcinoma **Key Point:** EGFR (Epidermal Growth Factor Receptor) mutations are the most common targetable molecular alteration in adenocarcinoma, particularly in non-smokers, occurring in 15–50% of cases depending on ethnicity and smoking status. ### Epidemiology of EGFR Mutations **High-Yield:** EGFR mutations are enriched in: - Non-smokers and light smokers (50–60% prevalence) - East Asian populations (40–50% prevalence) - Women - Adenocarcinoma histology (especially lepidic or acinar subtypes) ### Common EGFR Mutations | Mutation Type | Frequency | Clinical Significance | |---|---|---| | **Exon 19 deletion** | ~45% of EGFR-mutant cases | Sensitizing; excellent TKI response | | **Exon 21 L858R point mutation** | ~40% of EGFR-mutant cases | Sensitizing; excellent TKI response | | **Exon 20 insertion** | ~10% of EGFR-mutant cases | Resistant to standard TKIs | | **Exon 18 G719X** | ~5% of EGFR-mutant cases | Sensitizing; variable TKI response | ### Comparison with Other Molecular Alterations | Alteration | Adenocarcinoma Frequency | Smoking Association | Targetability | |---|---|---|---| | **EGFR mutation** | 15–50% | Non-smokers >> smokers | Yes (TKI) | | **KRAS mutation** | 25–35% | Smokers >> non-smokers | Limited (recently: sotorasib) | | **TP53 mutation** | 50–70% | Non-specific | No (current) | | **ALK rearrangement** | 3–7% | Non-smokers | Yes (ALK inhibitors) | | **ROS1 rearrangement** | 1–2% | Non-smokers | Yes (ROS1 inhibitors) | **Clinical Pearl:** EGFR-mutant adenocarcinomas typically present at advanced stage but have better initial response to targeted therapy (TKI) than EGFR wild-type tumors, which rely on chemotherapy or immunotherapy. **Mnemonic:** **EGFR in Non-smokers** — **E**GFR mutations are **E**nriched in **N**on-smoking adenocarcinoma patients, especially in **E**ast **A**sia. ### Therapeutic Implications 1. **First-generation TKIs** (erlotinib, gefitinib) — standard for sensitizing EGFR mutations 2. **Second-generation TKIs** (afatinib, dacomitinib) — for exon 20 insertions or resistant mutations 3. **Third-generation TKIs** (osimertinib) — for T790M resistance mutations **Warning:** TP53 mutations, while common in lung adenocarcinoma (~50–70%), are NOT specific to non-smokers and are not directly targetable. KRAS mutations are more common in smokers.